MYTX-011-01

• Research type

  Research Study

• Full title

  TITLE: A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer – KisMET-01

• IRAS ID

  1007533

• Contact name

  Shane McGann

• Contact email

  smcgann@mythictx.com

• Sponsor organisation

  Mythic Therapeutics, Inc.

• Clinicaltrials.gov Identifier

  NCT05907954

• Research summary

  The purpose of this research is to determine the safety and tolerability, and to aid in the selection of the best dose for future development, as well as measure any antitumour activity of a new antibody drug conjugate (ADC) called MYTX-011. MYTX-011 is a new drug, being studied in humans for the first time for treatment of advanced non-small cell lung cancer (NSCLC). The study team is investigating this drug to help treat lung cancers that are resistant to standard medications. This drug targets a protein called cMET on the cancer cell. MYTX-011 will attach to the cMET and release chemotherapy into the cancer cell.

• REC name

  West Midlands - Edgbaston Research Ethics Committee

• REC reference

  23/WM/0246

• Date of REC Opinion

  4 Jan 2024

• REC opinion

  Further Information Favourable Opinion